This study delves aims to evaluate the efficacy of durancin 61A as an inhibitor of resistant clinical pathogens and to shed light on its mode of action.
Browsing: Clinical > Clinical Diseases
0 Inhibition of MRSA and of Clostridium difficile by durancin 61A: synergy with bacteriocins and antibiotics
0 Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections
This perspective discusses the urgent need for novel and efficient antimicrobial strategies against C. difficile and the authors evaluate the application of the acyldepsipeptides family of antibiotics to treat C. difficile infections.